[University home]

The University of Manchester Library

Measurement of Insulin-Like Growth Factor-Ii in Human Plasma Using a Specific Monoclonal Antibody-Based 2-Site Immunoradiometric Assay

Crosby, S R; Anderton, C D; Westwood, M; Holly, J M P; Hughes, S C C; Gibson, M; Morrison, C A; Young, R J; White, A

Journal of Endocrinology. 1993;137(1):141-150.

Access to files

Full-text and supplementary files are not available from Manchester eScholar. Use our list of Related resources to find this item elsewhere.

Abstract

An immunoradiometric assay (IRMA) for the measurement of insulin-like growth factor-II (IGF-II) in human plasma has been developed, optimized and evaluated clinically in normal subjects and patients with disorders of the GH/IGF-I axis. Six monoclonal antibodies (MAbs) to recombinant human IGF-II (rhIGF-II) were produced, all of which had low cross-reactivity with rhIGF-I (<0.01%) and insulin (<0.01%). Compatibility of pairs of MAbs was tested in two-site IRMAs using three radioiodinated MAbs and three MAbs linked to Sephacryl S-300 (with separation of bound and free radiolabelled MAb by sucrose layering). Seven pairs of MAbs bound rhIGF-II and the combination of I-125-labelled W3D9 and W2H1 linked to solid phase was selected. The optimized assay had a completion time of 4 h, a minimum detection limit of 30 ng/ml (2.5 standard deviations from the zero standard) and detected a single peak of endogenous IGF-II in normal plasma which co-eluted with rhIGF-II after acid gel chromatography. IGF-II was measured in formic acid/acetone extracts of plasma from 16 normal subjects (mean 685, range 516-1008 mug/1), four acromegalic patients (mean 637, range 553-700 mug/1), fourteen patients with type-I diabetes (mean 635, range 247-753 mug/l), nine patients with uraemia (mean 423, range 78-850 mug/1), and three patients with Laron-type GH insensitivity (75, 35 and 36 mug/1). No significant fluctuations were detected between samples obtained hourly from 08.00 to 19.00 h in normal subjects. Low levels of IGF-binding proteins (IGFBPs) remaining in plasma extracts may interfere with the measurement of IGF-II and give rise to falsely elevated IGF-II levels in radioimmunoassays or falsely suppressed levels in IRMAs. Such interference did not occur with the IRMA when used to measure IGF-II in extracts from normal subjects, acromegalic patients and patients with type-I diabetes, and the addition of excess rhIGF-I in order to displace IGF-II from residual IGFBPs had no effect on IGF-II measurements in these samples. However, levels of IGF-II measured in extracts from. patients with Laron-type GH insensitivity and patients with uraemia increased markedly after preincubation with excess rhIGF-I. The accurate measurement of IGF-II by IRMA in extracts from these subjects therefore requires the displacement of IGF-II from IGFBPs prior to assay. We conclude that, in contrast to radioimmunoassays, the two-site IRMA developed here provides a practical, rapid and specific method for the measurement of IGF-II in human plasma.

Bibliographic metadata

Type of resource:
Content type:
Published date:
Volume:
137
Issue:
1
Start page:
141
End page:
150
Total:
10
Pagination:
141-150
ISI Accession Number:
ISI:A1993KW68900018
Related website(s):
  • Related website <Go to ISI>://A1993KW68900018
Access state:
Active

Institutional metadata

University researcher(s):

Record metadata

Manchester eScholar ID:
uk-ac-man-scw:151216
Created by:
Gibson, Martin
Created:
15th January, 2012, 15:04:07
Last modified by:
Gibson, Martin
Last modified:
1st February, 2013, 19:46:14